Nobuyuki Yamamoto

29.2k total citations · 5 hit papers
574 papers, 17.3k citations indexed

About

Nobuyuki Yamamoto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Nobuyuki Yamamoto has authored 574 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 441 papers in Pulmonary and Respiratory Medicine, 410 papers in Oncology and 91 papers in Molecular Biology. Recurrent topics in Nobuyuki Yamamoto's work include Lung Cancer Treatments and Mutations (389 papers), Lung Cancer Research Studies (181 papers) and Lung Cancer Diagnosis and Treatment (141 papers). Nobuyuki Yamamoto is often cited by papers focused on Lung Cancer Treatments and Mutations (389 papers), Lung Cancer Research Studies (181 papers) and Lung Cancer Diagnosis and Treatment (141 papers). Nobuyuki Yamamoto collaborates with scholars based in Japan, United States and United Kingdom. Nobuyuki Yamamoto's co-authors include Toshiaki Takahashi, Kazuhiko Nakagawa, Tony Mok, James Chih‐Hsin Yang, Martin Schüler, Lecia V. Sequist, Takashi Seto, Haruyasu Murakami, Victoria Zazulina and Masahiro Endo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nobuyuki Yamamoto

533 papers receiving 17.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

2015 715 citations James Chih‐Hsin Yang, Lecia V. Sequist et al. profile →
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 561 citations Takashi Seto, Terufumi Kato et al. profile →
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

2013 449 citations Takashi Seto, Katsuyuki Kiura et al. profile →
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

2017 308 citations Toshiaki Takahashi, Takeharu Yamanaka et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nobuyuki Yamamoto Japan	58	12.5k	11.6k	4.0k	2.5k	1.2k	574	17.3k
Yuichiro Ohe Japan	61	14.9k 1.2×	14.4k 1.2×	5.9k 1.5×	3.9k 1.5×	1.3k 1.0×	561	21.9k
Cesare Gridelli Italy	55	7.3k 0.6×	7.7k 0.7×	3.1k 0.8×	1.7k 0.7×	1.2k 0.9×	413	12.6k
Silvia Novello Italy	61	13.0k 1.0×	11.6k 1.0×	5.0k 1.2×	3.6k 1.4×	1.5k 1.2×	466	19.1k
Katsuyuki Kiura Japan	54	8.2k 0.6×	7.6k 0.7×	3.9k 1.0×	1.9k 0.7×	818 0.7×	578	12.5k
Hedy L. Kindler United States	61	7.3k 0.6×	8.4k 0.7×	3.6k 0.9×	3.1k 1.2×	1.8k 1.5×	400	16.1k
Masahiro Fukuoka Japan	55	16.7k 1.3×	15.2k 1.3×	6.1k 1.5×	3.3k 1.3×	1.2k 1.0×	266	22.5k
Joachim von Pawel Germany	64	16.9k 1.3×	17.7k 1.5×	7.2k 1.8×	3.2k 1.3×	1.3k 1.1×	254	25.0k
David Planchard France	58	10.0k 0.8×	11.0k 0.9×	4.6k 1.2×	3.4k 1.4×	842 0.7×	431	16.5k
Julian R. Molina United States	44	8.2k 0.7×	10.5k 0.9×	6.2k 1.6×	3.3k 1.3×	1.4k 1.2×	216	18.3k
Igor Bondarenko United States	54	9.0k 0.7×	13.3k 1.1×	3.3k 0.8×	3.6k 1.4×	1.2k 1.0×	317	17.7k

Countries citing papers authored by Nobuyuki Yamamoto

Since Specialization

Citations

This map shows the geographic impact of Nobuyuki Yamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuyuki Yamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuyuki Yamamoto more than expected).

Fields of papers citing papers by Nobuyuki Yamamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nobuyuki Yamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuyuki Yamamoto. The network helps show where Nobuyuki Yamamoto may publish in the future.

Co-authorship network of co-authors of Nobuyuki Yamamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Nobuyuki Yamamoto. A scholar is included among the top collaborators of Nobuyuki Yamamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobuyuki Yamamoto. Nobuyuki Yamamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations

Schöffski, Patrick, Patricia LoRusso, Nobuyuki Yamamoto, et al.. (2024). 56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma. ESMO Open. 9. 102446–102446. 3 indexed citations

Hata, Akito, Yoshihito Kogure, Masahide Oki, et al.. (2024). Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).. Journal of Clinical Oncology. 42(17_suppl). LBA8050–LBA8050.

Tachihara, Motoko, Akito Hata, Takaaki Tokito, et al.. (2023). Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L). JTO Clinical and Research Reports. 4(10). 100569–100569.

Akamatsu, Hiroaki, Shunsuke Teraoka, Shinkichi Takamori, et al.. (2022). Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical Cancer Research. 28(15). 3207–3213. 22 indexed citations

Takeda, Masayuki, Mototsugu Shimokawa, Atsushi Nakamura, et al.. (2021). A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical Lung Cancer. 22(4). 376–380. 5 indexed citations

Nakagawa, Kazuhiko, Ernest Nadal, Edward B. Garon, et al.. (2021). RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(19). 5258–5271. 29 indexed citations

Sawa, Kenji, Jun Oyanagi, Mitsuru Fukui, et al.. (2021). Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Translational Oncology. 14(7). 101102–101102. 11 indexed citations

Miyawaki, Taichi, Hirotsugu Kenmotsu, Hideyuki Harada, et al.. (2021). Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer. 21(1). 1121–1121. 5 indexed citations

10.

Masuda, Noriyuki, Yuichiro Ohe, Akihiko Gemma, et al.. (2019). Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan. Cancer Science. 110(4). 1401–1407. 19 indexed citations

11.

Akamatsu, Hiroaki, Shunsuke Teraoka, Yasuhiro Koh, et al.. (2018). A Phase II Study of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). Clinical Lung Cancer. 20(2). 139–141. 5 indexed citations

12.

Akamatsu, Hiroaki, Hideyuki Harada, Shoji Tokunaga, et al.. (2018). A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). Clinical Lung Cancer. 20(1). e25–e27. 18 indexed citations

13.

Otsubo, Kohei, Junji Kishimoto, Hirotsugu Kenmotsu, et al.. (2017). Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non–Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer. 19(1). e5–e9. 35 indexed citations

14.

Schüler, Martin, Yi‐Long Wu, Vera Hirsh, et al.. (2016). First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. QUT ePrints (Queensland University of Technology). 1 indexed citations

15.

Murakami, Haruyasu, Nobuyuki Yamamoto, Taro Shibata, et al.. (2014). A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer. 84(1). 67–72. 53 indexed citations

16.

Sequist, Lecia V., James Chih‐Hsin Yang, Nobuyuki Yamamoto, et al.. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27). 3327–3334. 2461 indexed citations breakdown →

17.

Yagishita, Shigehiro, Hidehito Horinouchi, Tomoko Yorozu, et al.. (2013). Secondary Osteosarcoma Developing 10 Years after Chemoradiotherapy for Non-small-cell Lung Cancer. Japanese Journal of Clinical Oncology. 44(2). 191–194. 1 indexed citations

18.

Yamamoto, Nobuyuki, et al.. (2009). Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors. Japanese Journal of Clinical Oncology. 39(4). 260–266. 48 indexed citations

19.

Igawa, Satoshi, Nobuyuki Yamamoto, Shinya Ueda, et al.. (2007). Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer. Journal of Thoracic Oncology. 2(8). 741–744. 32 indexed citations

20.

Takeda, Yuko, Toshihide Asou, Nobuyuki Yamamoto, et al.. (2005). Arch Reconstruction without Circulatory Arrest in Neonates. Asian Cardiovascular and Thoracic Annals. 13(4). 337–340. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact